Raksibakumab
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Intravenozno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 15-19 dana |
| Identifikatori | |
| CAS broj | 565451-13-0  |
| ATC kod | None |
| DrugBank | DB08902 |
| Hemijski podaci | |
| Formula | C6320H9794N1702O1998S42 |
| Molarna masa | 142.93 |
Raksibakumab[1] je ljudsko monoklonalno antitelo namenjeno profilaksnoj primeni i lečenju udahnutog antraksa.[2][3][4] Njegova efikasnost je porvđena na zečevima i majmunima.[5]
Reference[уреди | уреди извор]
- ^ Mazumdar, Sohini (2009). „Raxibacumab”. MAbs. 1 (6): 531—538. PMC 2791309
. PMID 20068396. doi:10.4161/mabs.1.6.10195.
- ^ Mazumdar S: Raxibacumab. MAbs. 2009 Nov-Dec;1(6):531-8. Epub 2009 Nov 29. PMID 20068396
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Migone, TS; Subramanian, GM; Zhong, J; Healey, LM; Corey, A; Devalaraja, M; Lo, L; Ullrich, S; Zimmerman, J (2009). „Raxibacumab for the treatment of inhalational anthrax”. The New England Journal of Medicine. 361 (2): 135—44. PMID 19587338. doi:10.1056/NEJMoa0810603.
Literatura[уреди | уреди извор]
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
